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Synopsis 
The goal of this manuscript is to provide clinical guidance on breast cancer screening and 
prevention in primary care. The discussion highlights the importance of risk assessment, including 
screening options and risk reduction strategies for women at average and high risk. We review 
recommendations for breast cancer screening, evaluate current evidence on primary prevention, examine 
current practice patterns, and consider the impact of recent changes within health care. 
 
Key Points for Breast Cancer Screening and Prevention 
• Risk assessment is a key component for determining an individual’s options for breast cancer 
screening and prevention. 
• A primary care clinician needs to be able to identify risk factors that place a woman at higher than 
average risk for breast cancer, and if needed, place the appropriate referral for genetic 
counseling and risk reduction assessment. 
• Mammography is universally recommended for women ages 50 to 74, with the frequency of 
screening (annually or biennially) to be determined by individual patient preferences and a 
balance of net harms and benefits. 
• While  guidelines generally recommend offering screening for women ages 40 to 49, some place 
additional emphasis on a shared decision making model between patient and providers. 
• Preventive measures such as physical activity, tobacco cessation, limiting alcohol use, and 
maintaining a healthy weight should be encouraged for all women to reduce breast cancer risk, 
and chemoprevention with selective estrogen receptor modulators is an important consideration 
for women at high risk from breast cancer. 
 
Introduction 
Breast cancer–the most common noncutaneous cancer among women in the United States—kills 
more women every year than nearly all other cancers, falling only second to lung cancer.(1, 2) 
Surveillance estimates suggest over 230 000 women will be diagnosed with breast cancer in 2014, and 
the disease will claim an estimated 40 000 lives.(3) 
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In the 1980s and 1990s, the incidence of diagnosed breast cancer rose due to an increase in 
mammography screening. The incidence then decreased sharply from 2002 to 2003, largely attributable 
to a reduction in the use of hormone replacement therapy following findings from the Women’s Health 
Initiative.(4) Since 2003, the incidence of diagnosed breast cancer has remained relatively stable.(1) 
Mortality rates from breast cancer have declined steadily since 1990. Among women younger 
than 50, death rates have decreased on average by 3.2% per year; the rate of decline has been slightly 
lower in women older than 50, at approximately 2.0% per year.(5) Continued improvements in cancer 
detection and treatment are the primary reasons for this drop;(6) however, not all segments of the 
population have benefited equally. Mortality rates, for example, have declined more slowly among blacks 
than whites, despite blacks’ lower incidence rate. Age-adjusted mortality based on 2006-2010 
surveillance data show the breast cancer incidence rate was 121.4 cases per 100,000 black females vs 
127.4 cases per 100 000 white females; mortality, however, was 30.8 deaths per 100 000 black females 
vs 22.1 deaths per 100 000 white females.(5) The five-year (2003-2009) relative survival rate is also lower 
for black females vs white females, at 78.7% vs 90.4%, respectively.(5) This disparity has been attributed 
to multiple factors, including more aggressive tumors, social conditions, access to high quality health 
care, differences in detection (including screening behaviors), health system factors, and treatment 
differences.(7-12)  
 
Risk Assessment for Breast Cancer 
Risk factor assessment is critically important for breast cancer screening. Women should be 
divided into high risk or average risk categories to guide screening options and risk reduction strategies. 
While screening programs traditionally use age as the primary risk factor, the individual’s collective risk 
factors determine the net benefits and harms of additional screening, such as genetic testing, or 
interventions to reduce risk, such as chemoprevention. 
Risk Factors 
Age. The most important risk factor for breast cancer is age. Approximately 10% of women are 
diagnosed between ages 35 and 44, 22% are diagnosed between ages 45 and 54, and 25% are 
diagnosed between ages 55 and 64. Median age for diagnosis is 61 years, while the median age at death 
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is 68 years.(5) 
Family history and heritable gene mutations. Family history of breast or ovarian cancers on 
either the maternal or paternal side are also important risk factors, particularly in women diagnosed 
younger than 45 years of age.(13) Women who have one first-degree female relative with breast cancer 
have a 1.8 times higher risk of developing breast cancer compared to women with no family history. 
Having two first-degree relatives with breast or ovarian cancer increases breast cancer risk by almost 3-
fold; for women with three or more relatives, risk jumps by almost 4-fold.(14) An estimated 10% of breast 
cancers can be attributed to an inherited gene mutation. BRCA1 and BRCA2 gene mutations are involved 
in hereditary breast and ovarian cancers, which occur with higher frequency in certain ethnic groups such 
as the Ashkenazi Jewish population. Other more rare mutations include TP53 and PTEN, which are 
associated with Li-Fraumeni syndrome and Cowden syndrome, both of which lead to an increased risk for 
breast cancer. The mutation in the CDH1 gene involved with hereditary diffuse gastric cancer also 
predisposes women to an increased risk for lobular breast cancer.(13)  
Clinical factors. Clinical factors that increase the risk of breast cancer include a history of 
proliferative lesions with atypia, history of chest irradiation, and breast density. Atypical ductal hyperplasia 
and atypical lobular hyperplasia increase risk by about 4 to 5 times compared to the average woman.(15) 
Risk is approximately doubled to 8 to 10 times for women with lobular carcinoma in situ (LCIS).(16) 
Women who received high-dose chest radiation at a younger age (≤ 30 years), such as for Hodgkin 
lymphoma, have higher incidence rates starting about 8 years after radiation treatment.(17) High breast 
tissue density, a measure of the amount of glandular tissue relative to fatty tissue in the breast, has been 
shown to be a strong risk factor for the development of breast cancer.(18) Women with high breast tissue 
density have a 4 to 6 times increased risk of breast cancer compared to women with less dense breast 
tissue.(19-21) High density breast tissue also makes the detection of breast cancer by mammography 
more difficult.(20) 
Reproductive factors. Factors that involve prolonged hormonal exposure may increase the risk 
for developing breast cancer, including early menarche, low parity, older age at first live birth, late 
menopause, and hormone replacement therapy (estrogen plus progestins). Conversely, factors that may 
be associated with decreased hormonal exposure, such as premature menopause (before age 40), may 
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decrease the risk for developing breast cancer.(22) Other factors that may confer a protective effect 
include a younger age at first full-term pregnancy (<30 years), a higher number of pregnancies,(23) and 
breastfeeding, particularly for more than one year.(24) A summary of the important risk factors for breast 
cancer is listed in Table 1. 
Risk Factor Tools 
The National Cancer Institute developed a tool based on the Gail model to estimate a woman’s 5-
year risk and lifetime risk of invasive breast cancer.(25) This instrument—the Breast Cancer Risk 
Assessment Tool—includes reproductive risk factors (age of menarche, parity, age at first birth, 
breastfeeding, age at menopause), first-degree relatives with breast cancer, previous breast biopsies with 
or without atypical hyperplasia, and race. It is accessible online for free at 
http://cancer.gov/bcrisktool/default.aspx. However, the model cannot be applied to women who are 
younger than 35 years old or who have LCIS, ductal carcinoma in situ, or invasive cancer. It is also not 
appropriate for women with a strong family history of breast cancer, as it does not include maternal 
second- or third-degree relatives with breast cancer, paternal family history, male breast cancer, or 
ovarian cancer.(26) For women with a strong family history of breast or ovarian cancer, other statistical 
models should be utilized (BRCAPRO,a BOADICEA,b Claus).(27) For more information about the various 
instruments go to the following National Cancer Institute webpage: 
http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/page1. If the 
lifetime risk for an individual woman is ≥20%, then increased surveillance with different imaging studies 
and risk reduction options should be reviewed with a health care professional.(13) 
The primary care clinician. The primary care clinician’s role involves identifying women who 
have a greater than average lifetime risk of developing breast cancer and designing a screening and risk 
reduction strategy in concert with the patient. The identification of women who meet criteria to consider 
genetic testing and their referral to a genetic counselor constitutes a clear primary care responsibility. The 
referral criteria for genetic testing for hereditary breast and ovarian cancer syndrome and further genetic 
risk assessment is reviewed in List 1 and Table 2. Additional online resources on how to order genetic 
testing and how to find a genetic counselor are available in Box 1.  
                                                        
a
 http://bcb.dfci.harvard.edu/bayesmendel/brcapro.php  
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Breast Cancer Prevention 
A summary of recommendations for the primary prevention of breast cancer is outlined in List 2. 
Obesity, Physical Activity, Dietary Content 
Obesity is a risk factor for postmenopausal breast cancer, as a higher amount of fat tissue 
increases estrogen levels and subsequent risk. Weight gain specifically has been associated with an 
increased risk for breast cancer.(28) In a prospective cohort of over 80 000 women, those who gained 55 
pounds or more after age 18 years had an almost 50% higher risk of breast cancer. After menopause, 
women who gained 22 pounds or more had an 18% higher risk.(29) Data on weight loss in relation to 
breast cancer risk is less clear. The Nurses' Health Study showed women with a sustained weight loss of 
≥22 pounds since menopause and who had never used postmenopausal hormone replacement therapy 
had a lower breast cancer risk than women who simply maintained their weight.(29) However, another 
prospective cohort study in postmenopausal women found no association between a median weight loss 
of 11 pounds and a reduction in breast cancer, though this weight loss was not sustained in all women 
during the 5 year follow-up.(30) Studies in women who have undergone bariatric surgery suggest that 
surgical weight loss may be associated with a decreased risk of breast cancer.(31)(32) Using simulation 
modeling data, about 5.5% of breast cancer cases expected to occur in the year 2025 will be attributable 
to obesity. By 2025, the authors estimated there would be about 3300 to 5700 fewer breast cancer deaths 
in women age ≥25 years if obesity was eradicated.(33)  
There is growing evidence of a decreased risk of breast cancer with increased physical activity, 
particularly for postmenopausal women and women with hormone receptor negative tumors.(34, 35) The 
European Prospective Investigation into Cancer and Nutrition—a large prospective cohort study including 
over 250 000 women—found an inverse association between breast cancer risk and moderate to high 
levels of total physical activity compared to those lowest in physical activity. For women diagnosed after 
age 50 years, the largest risk reduction was associated with the highest amount of physical activity; for 
women diagnosed before age 50 years, the largest risk reduction was associated with moderate total 
physical activity. Both estrogen-receptor-positive and progesterone-receptor-positive cancers were 
                                                                                                                                                                                   
b
 http://ccge.medschl.cam.ac.uk/boadicea/  
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inversely associated with moderate and high physical activity, suggesting that increased activity may 
lower concentrations of hormones and their related effect on estrogen sensitive tumors. Other 
mechanisms through which physical activity may mitigate risk include reduced chronic inflammation, 
increased antioxidant enzymes, and an improved immune system.(36)  
The data linking dietary factors to breast cancer risk remains inconclusive and inconsistent. Three 
large reviews including prospective studies did not show a strong association between dietary factors 
(fruit and vegetables, total fat intake, fat biomarkers, vitamins [A, C, E, and beta-carotene], antioxidants, 
carbohydrates, dairy, soy) and risk for breast cancer.(37-39) A recent prospective study specifically 
looked at the role of total dietary fiber and its main food sources (vegetables, fruit, cereals, and legumes) 
with relation to breast cancer risk. After a median follow-up of 11.5 years, they found that a high dietary 
intake of total fiber and a high intake of fiber from vegetables were both associated with a decreased 
breast cancer risk, but not fiber from fruit, cereals, or legumes. The association between fiber and breast 
cancer risk was not modified by body mass index, waist-hip ratio, or alcohol consumption. The role of 
dietary fiber still remains unclear in breast cancer risk, and further studies are needed to elucidate the 
relationship between dietary content and breast cancer prevention.(40)  
Tobacco  
Studies have shown a strong association between current and previous tobacco use and risk of 
breast cancer. In a prospective cohort study of almost 80 000 women, current smokers had a 16% higher 
risk of breast cancer and former smokers had a 9% increased risk over non-smokers. This increased 
breast cancer risk remained up to 20 years after smoking cessation. For nonsmokers, a very high 
exposure to passive smoking (defined as ≥10 years' exposure in childhood, ≥ 20years' exposure as an 
adult at home, and ≥10 years' exposure as an adult at work) resulted in a 32% increased risk of breast 
cancer compared with those never exposed to secondhand smoke.(41) Another study including nearly 
3000 women found a significant increased risk of all-cause mortality in women who smoked either 15–24 
cigarettes or 25+ cigarettes per day, with the highest risk for women who smoked the highest quantity. 
Overall, women who smoked for 20+ pack-years had a 54% increase in breast cancer mortality and an 
81% increase in all-cause mortality.(42) 
Alcohol  
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Alcohol use has been found to be associated with an increased risk of breast cancer in a number 
of studies.(43-45) Women who consumed 3 to 14 drinks per week had a 12% increased risk of breast 
cancer for every drink (10 g of alcohol) consumed per day(46); this dose-dependent risk is independent of 
the specific type of alcoholic beverage.(43, 45, 46) The mechanism linking alcohol consumption to 
increased breast cancer risk may be alcohol’s capacity to raise circulating concentrations of sex 
hormones.(46-48) Evidence does not support an association between alcohol intake and increased 
breast cancer risk among women who were past users or are current users of hormone replacement 
therapy when compared to those never using the therapy.(46, 49-51)  
Chemoprevention for Patients at High Risk: Selective Estrogen Receptor Modulators (SERMS) 
Randomized trials have shown that chemoprevention with drugs like tamoxifen and raloxifene 
reduce breast cancer risk. In 1998, the first randomized trial with over 13 000 women demonstrated that 
tamoxifen could reduce the risk of breast cancer in high-risk women with estrogen receptor positive 
tumors.(52) Breast cancer risk was decreased by 42% in the tamoxifen group after an average of 7 years 
of follow up compared to the control group. This protective effect continued for up to 10 years after 
completion of the 5-year treatment. Although tamoxifen was associated with a lower risk of breast cancer, 
the net benefit was reduced as a result of an increase in the risks of endometrial cancer, stroke, venous 
thromboembolism, cataracts, and vasomotor symptoms. However, tamoxifen also demonstrated the 
potential benefit of fracture reduction, particularly in postmenopausal women.(53, 54) Despite this 
decrease in breast cancer risk, no trials with tamoxifen have shown an effect on all-cause mortality or 
breast cancer-specific mortality.(55-58) 
Raloxifene, a drug originally studied for osteoporosis prevention, was also observed to decrease 
the risk of breast cancer.(59) In the Study of Tamoxifen and Raloxifene trial, raloxifene was nearly as 
effective as tamoxifen in preventing invasive breast cancer and had a lower risk of side effects. As 
observed with tamoxifen, this risk reduction effect applies only to the development of estrogen receptor 
positive breast cancer. No difference was found in the number of deaths between tamoxifen and 
raloxifene.(60) Other trials have also failed to show a mortality benefit for raloxifene, but notably, they 
lacked sufficient power to detect significant differences in mortality over their course of follow-up.(61, 62)  
An updated meta-analysis of over 80 000 women found that 4 SERMS (tamoxifen, raloxifene, 
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arzoxifene, and lasofoxifene) reduced breast cancer by 38% compared to the control group. An increased 
rate of endometrial cancer was mostly limited to the tamoxifen trials. Risk for venous thromboembolism 
was similar between tamoxifene and raloxifene, with a slightly increased rate with arzoxifene and 
lasofoxifene. All SERMS had similar risk reduction for fractures, and no effect of SERMs was found for 
myocardial infarction, stroke, or transient ischemic attacks.(54) 
Due to risk of adverse effects, SERMS are recommended only for women at high risk for breast 
cancer. The National Comprehensive Cancer Network® Clinical Practice Guidelines In Oncology (NCCN 
Guidelines®) for Breast Cancer Risk Reduction recommend tamoxifen as an option in women 35 years or 
older, with a life expectancy ≥10 years, who have had LCIS, or have a ≥1.7% 5-year risk for breast cancer 
by the modified Gail model.(63) Tamoxifen is the more favorable choice of a risk reduction agent 
compared to raloxifene for most postmenopausal women, based on results that showed less continued 
benefit of raloxifene compared to tamoxifen after cessation.(60, 63) 
 
Breast Cancer Screening for Women at Average Risk 
A summary of recommendations for breast cancer screening in average-risk women is listed in 
Table 3. 
Mammography  
Ages 40-49 years. Multiple studies have evaluated the benefits and harms of screening in 
women age 40 years and older, but few have specifically evaluated the age group of women aged 40 to 
49. The Age Trial looked specifically at women between the ages of 39 and 41 years, who were 
randomized to participate in annual mammography until age 48. The reduction in breast cancer mortality 
in the test group was not statistically significant after 10.7 years of follow up; however, adjusting for non-
compliance in women actually screened showed an estimated 24% reduction in mortality risk. Moreover, 
a meta-analysis of 8 trials (including the Age Trial) showed a 16% reduced risk in breast cancer 
mortality.(64) Some of this benefit is likely attributable to the inclusion of women up to age 49 years at 
entry in all studies except the Age Trial.(50) In a re-analysis of the Gothenburg trial looking at women 
aged 39 to 49 years, screening mammography was found to reduce risk by 31% for breast cancer 
mortality after 13 years of follow-up.(65) After combining data from 7 randomized trials— only 3 of which 
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employed adequate randomization—an updated Cochrane review found a 19% risk reduction in breast 
cancer mortality after 7 years and a 20% reduction after 13 years; however, when the three trials with 
adequate randomization were examined alone  no statistically significant effect was detected(66)  
Conducting its own systematic review, the United States Preventative Services Task Force 
(USPSTF) reported that mammography reduces breast cancer mortality by 15% for women aged 40-49 
years, with an overdiagnosis estimates varying between 1% and 10%.(67); these findings are similar to 
those reported by the Canadian Task Force on Preventive Health Care (CTFPHC).(68) Both the USPSTF 
and CTFPHC report an increased rate of false positives in women aged 40-49 years; hence, they both 
recommend that women ages 40 to 49 make an informed and shared decision whether or not to 
participate in mammography screening; neither group endorses routine screening of all women aged 40-
49 years in the absence of shared decision making.(67, 68) Other groups—notably, the American College 
of Obstetricians and Gynecologists (ACOG), the American Cancer Society (ACS), and the NCCN®—
continue to recommend routine screening in women 40 to 49. These groups cite evidence that the 
mortality risk reduction associated with screening younger women is comparable to the benefit observed 
in screening older women(69-71). They also judged that the balance of benefits and harms favored a 
strategy of routine screening for all younger women. In addition, a large case control study published after 
release of the USPSTF and CTFPHC guidelines suggests a lack of screening in women aged 40 to 49 
years is associated with a higher death rate from breast cancer. Among 609 confirmed breast cancer 
deaths, 71% occurred in women who were not screened regularly while 29% occurred in women who had 
been screened with mammography. In this study, the death rate from breast cancer was actually higher in 
women aged <50 years compared to women aged ≥50 years.(72) 
Ages 50-69 years. Screening mammography in women aged 50 to 69 years has been proven in 
multiple randomized trials to reduce breast cancer mortality from 15-20%.(65-68, 73-79) Based on the 
higher incidence of breast cancer in this age group and the evidence of reduction on breast cancer 
mortality, cancer screening guidelines continue to recommend screening mammography. However, there 
is still debate over the frequency at which screenings should occur. The USPSTF commissioned 
screening models by 6 independent groups within the Cancer Intervention and Surveillance Modeling 
Network to identify the most efficient screening strategy. The investigators found that the method of 
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starting screening at age 50 years and continuing biennially to age 69 years strikes the right balance 
between decreasing breast cancer mortality against potential harms.(80) However, some guideline 
groups continue to recommend offering annual screening, whereas others emphasize that the decision 
about screening frequency should be shared with the patient, based on their personal values. 
Ages 70 years and over. Results from the Swedish Two-County trial of women aged 70 to 74 
years showed no reduction in mortality with breast cancer screening.(77) However, the CTFPHC notes 
that the absolute benefits of mammography in women aged 70 to 74 years are likely comparable to those 
for women aged 50–69 years due to the higher absolute risk in older women. The CTFPHC therefore 
recommends routine mammography every two to three years in women aged 70 to 74 years as a weak 
recommendation based on low-quality evidence.(68) Similarly, the USPSTF continues to recommend 
biennial screening until age 74 for women who are in good health.(67) Overall, the decision to continue 
screening beyond the age of 75 years should take into account individual patient circumstances and 
preferences. 
Breast Ultrasound 
Breast ultrasound has been studied particularly for screening women with high breast density due 
to the lower sensitivity of mammography in these patients. One study found that 42% of all women with 
nonpalpable invasive breast cancer had their cancers detected only with screening ultrasound, and 37% 
of all cancers in women with dense breasts were detected only with screening ultrasound.(81) In another 
study of women with dense breast tissue who received either mammography plus ultrasound or 
mammography alone, supplemental ultrasound detected an additional 4.2 cancers per 1000 women.(82) 
While these studies show promising results for the use of ultrasound in women with high breast density, 
at this time there is no recommendation for performing ultrasound as part of routine breast cancer 
screening. 
Breast Self-Examination  
A few large trials have analyzed the effect of instructing women in breast self-examination (BSE) 
on reducing breast cancer mortality. The UK Trialists study, a nonrandomized study with 16 years of 
follow up, showed no significant difference in breast cancer mortality between the BSE and control 
groups.(83) A Cochrane review included randomized trials comparing BSE to control groups in both 
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Russia(84) and Shanghai,(85) with each study showing no significant differences in breast cancer 
mortality after 13 and 11 years, respectively.(86) Furthermore, these trials show women performing BSE 
had an increased number of breast biopsies (53%) and they were not more likely to be diagnosed with 
breast cancer compared to women who were not taught BSE after 5 years of follow-up.(87) Another study 
showed that women 40 and older who performed more frequent or longer BSE were more likely to have a 
diagnostic mammography or ultrasound.(88) Overall, these findings do not support regular BSE as an 
effective screening method for decreasing breast cancer mortality. 
Although no screening organization now recommends routine instruction of women in BSE, 
several organizations making recommendations do promote the concept of breast self-awareness. The 
ACS, the NCCN®, and ACOG all promote teaching patients about breast self-awareness, the concept that 
a woman should be familiar with her own breasts and bring any changes to the attention of her health 
provider. Women should still be encouraged to report new breast changes, but they are not advised to 
perform a specific self-examination technique.(69-71) 
Clinical Breast Examination  
The efficacy of the clinical breast examination (CBE) has been investigated in a few large trials. In 
community settings assessing CBE as part of the National Early Detection Program, CBE detected 5.1% 
of breast cancers that were not detected by mammography and therefore could have been missed with 
mammography alone. The procedure for conducting a CBE was not reported, but the estimated sensitivity 
(ability of the test to correctly identify those patients with the disease (89)) for CBE was 58.8% and 
specificity (ability of the test to correctly identify those patients without the disease (89)) was 93.4%,(90) 
similar to previous estimates. In a Canadian study of 300 000 women aged 50 to 69, CBE increased the 
rate of detection of small invasive cancers over mammography alone by a small amount, between 2% to 
6%. Trained nurses or physicians performed the CBE, which included visual inspection followed by a 
systematic 10-minute examination.(91) None of these trials showed a significant difference in breast 
cancer mortality between screening with combined mammography and CBE compared to mammography 
alone.(92)  
The USPSTF found a lack of evidence to recommend for or against breast cancer screening with 
CBE apart from mammography.(93) The utility of CBE as a detection method, however, has relied on its 
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performance characteristics. The variation of CBE techniques performed by clinicians makes it 
challenging to assess the efficacy of the clinical examination in routine practice, which may not meet the 
standards of the Canadian trial. Most professional guideline groups advocate incorporating CBE as long 
as it is performed correctly. Per the ACS recommendations, after visual inspection and palpation of lymph 
nodes, the examiner should use the pads of the middle three fingers using circular motions, to cover the 
area down the midaxillary line, across the inframammary ridge at the fifth/sixth rib, up the lateral edge of 
the sternum, across the clavicle, and back to the midaxilla. A vertical strip pattern is preferred over the 
concentric circle pattern, and the exam should palpate at increasing levels of pressure (superficial, 
intermediate, and deep).(94)  
 
Breast Cancer Screening for Women at High Risk 
The recommendations for screening and risk reduction for women at high risk from breast cancer 
are summarized in Table 4. 
Magnetic Resonance Imaging 
In April 2007, the ACS released guidelines on the use of annual breast magnetic resonance 
imaging (MRI) in addition to mammography for breast cancer screening in women at high risk. This 
includes women who have an approximate lifetime risk ≥20%; namely, those who are BRCA mutation 
carriers, first-degree relatives of known BRCA mutation carriers who have not undergone genetic testing, 
women who received chest irradiation between 10 and 30 years ago, Li-Fraumeni syndrome and first-
degree relatives, Cowden and Bannayan-Riley-Ruvalcalba syndromes and their first-degree relatives. 
Insufficient evidence for screening with MRI exists for LCIS, atypical ductal hyperplasia, heterogeneously 
dense breasts, women with a personal history of breast cancer, or women with a lifetime risk <20%.(95) 
Although not exclusive to BRCA 1 and 2 carriers, MRI combined with mammography has a higher 
sensitivity compared to mammography alone (70%-97% and 23%-41%, respectively)(96); however, 
specificity is lower with the combined method (75%-97%) versus mammography alone (93%-99%) 
because of the high number of false positives with MRI(96).  Although studies show that breast MRI 
screening of BRCA1 and BRCA2 mutation carriers detects breast cancer earlier and more frequently than 
mammography, none has demonstrated an improvement in mortality or survival, largely related to the 
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difficulty in conducting adequately large clinical trials.(96-103)  
NCCN® recommendations for women who are BRCA1/BRCA2 mutation carriers includes breast 
awareness starting at age 18, a clinical breast exam every 6 to 12 months, annual mammogram and MRI 
starting at age 25, a discussion of risk-reducing mastectomy and risk-reducing salpingo-oophorectomy, 
and consideration of chemoprevention.(13) For a more detailed discussion, see NCCN Guidelines® 
Genetic/Familial Risk Assessment for Breast Cancer.(13) 
 
Current Practice Patterns 
The release of the 2009 USPSTF recommendations instigated public debate among advocacy 
and specialty organizations regarding the changes to individualized consultation and decision making for 
screening mammography for the 40 to 49 age group. Initial studies have assessed changes to practice 
patterns since the new recommendation. The National Health Interview Survey asked 27, 829 women 
aged 40 and over to self-report mammography screening in the past year. Although there was a slight 
increase in the age-adjusted rates of self-reported mammography from 2008 to 2011, 2011 rates were 
not significantly different compared with 2008 for women in any age group.(104) Similarly, the Medical 
Expenditure Panel Surveys analyzed the biennial mammography rate for almost 30, 000 women in 3 
different age groups (40 to 49, 50 to 74, and 75 and older), and found no statistically significant difference 
in mammography rates between 2010 and earlier years (pooled rate 2006-2009) for any age group.(105) 
Various studies have also evaluated screening preferences and differences based on specialty. 
In a web-based survey (106) of 11, 922 primary care physicians, over 95% recommended screening 
mammography to women aged 50-69 years, regardless of specialty. However, for women 40-49 years 
old, 94% of obstetrician gynecologists always recommended mammography compared to 81% of internal 
medicine physicians and 84% of family medicine physicians. Similarly, for women ages 70 and older, 
86% of obstetrician gynecologists always recommended screening mammography compared to 67% for 
internal medicine and 59% for family medicine physicians.  
Another survey (107) led by the National Cancer Institute asked 1212 primary care physicians 
about their breast cancer screening practices. The ACS guidelines were cited as the most influential 
(56%), followed by ACOG (47%), USPSTF (42%), American Academy of Family Physicians (32%), and 
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American College of Physicians (25%) guidelines. More than two-thirds of all physicians recommended 
mammography to women 40 to 49 annually compared to greater than 90% of all physicians who 
recommended annual mammography to women 50 years and over. Also, both family medicine and 
internal medicine physicians were more likely to no longer recommend screening at a certain age (30.2% 
and 37.8%, respectively) than obstetrician gynecologists (14%).(109) Despite the varying 
recommendations, ultimately it is the responsibility of the provider to discuss the net harms and benefits 
of breast cancer screening with each patient to determine individual screening preferences. 
 
Barriers to Delivery 
Despite having access to health care, many women are not being screened.(108) National 
Medicare data demonstrate that only 64% of eligible woman (65 and older) have had a mammogram 
within the previous two years. Screening rates in Medicare-eligible women who have family incomes less 
than 100% of the federal poverty rate are even lower (51%).(109) Furthermore, use of screening 
mammography varies by race and ethnicity. Hispanic, Asian, and foreign-born women who have lived in 
the United States for less than 10 years have lower rates of screening compared to other women.(108) 
Several factors influence a woman’s decision to obtain screening services. According to one 
systematic review, barriers that affect a woman’s decision to obtain screening include concerns about 
mammography safety, pain associated with the procedure, language and cultural differences, provider 
biases, lack of social support, and lack of knowledge.(110) A report by the Institute of Medicine in 2003 
revealed a major influencing factor was a woman’s knowledge about the risk of breast cancer and the 
benefits of screening.(111) In a study of 20 focus groups with women from multiple racial and ethnic 
backgrounds (112), the major reasons for not getting a repeat mammogram included concerns about test 
efficacy, time needed to schedule appointments, competing family demands, and concern about radiation 
exposure. Regardless of age, some women did not think they were at high risk for breast cancer due to a 
negative family history.The most commonly cited barriers to breast cancer screening in a 2006 survey of 
primary care physicians (113) included a lack of patient follow through on mammography, lack of 
insurance coverage for screening, and lack of time to discuss screening. These barriers could be better 
addressed if providers were aware of the aforementioned patient concerns and the lack of education on 
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screening.  
Another challenge to breast cancer screening is ensuring appropriate follow-up of abnormal 
results. Minority women and those with poorer socioeconomic status are less likely to have timely follow-
up after abnormal screening results and are more often diagnosed with late-stage disease. In a study of 
women with late-stage breast cancer at the time of diagnosis, 52% were not screened according to 
guidelines and 8% did not receive timely follow-up of their abnormal mammograms.(114) However, a 
wide variability in quality of care exists for cancer screening diagnosis and follow-up of abnormal tests, 
even among patients with insurance.(115) 
Racial disparities in breast cancer include the discrepancy in mortality rates between blacks 
compared to whites. Cook County (Illinois, USA) investigators who analyzed 25, 900 cases of breast 
cancer found that black women were more likely to be diagnosed at later stages than white women at any 
age after evaluating by stage, geocode, race/ethnicity, and socioeconomic status. Hispanic women were 
also likely to have a later diagnosis than white women up until about age 68. Poverty was also a predictor 
of being diagnosed with breast cancer at a later stage.(116) In another study, black women had a 
statistically significant lower 5-year survival rate (55.9%) compared to white women (68.8%). After 
matching for presentation characteristics, white patients were more likely to receive treatment compared 
to black patients, mean time from diagnosis to treatment was longer for black patients, and black patients 
were less likely to receive treatment with chemotherapy and more likely to receive breast-conserving 
surgery without other treatment compared to white patients. These presentation characteristics accounted 
for the majority of the difference in the absolute survival rates between black and white women. 
Compared to white patients, black patients had a poorer state of health at time of diagnosis with a higher 
number of comorbidities, more advanced disease, and worse prognostic features (eg, estrogen receptor 
status).(117)  
 
Impact of Changes Within Health Care 
Affordable Care Act  
A review including 195 research studies with 4.8 million United States women found that a lack of 
health insurance was a major predictor of women not obtaining mammography.(110) As the Affordable 
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Care Act is fully implemented, the expansion of Medicaid along with subsidized state insurance 
exchanges and elimination of cost sharing is expected to improve access to breast cancer screening for 
many women. The United States Census Bureau’s 2009 American Community Survey of adults aged 18 
to 64 estimated that about 2.8 million low-income women aged 40 to 64 will gain health insurance as a 
result of the Affordable Care Act.(118) This translates into an additional 500 000 women who will receive 
breast cancer screening in the first year of the act, and an estimated additional 1 million more over the 
subsequent 2 years.(116)  
Patient-Centered Medical Home and the Electronic Health Record 
The creation of a patient-centered medical home (PCMH) focused on preventive health and care 
coordination will help deliver cost effective, efficient primary care. In order to accomplish this goal, PCMH 
approaches to care need to effectively identify women who are eligible to be screened, particularly 
targeting under-screened groups such as racial and ethnic minorities. Health assessment tools, detailing 
a complete family history, the clinical team, and electronic health record (EHR) systems can help to 
identify people who should be screened. The EHR can flag patients who are at high risk based on 
personal and family risk factors entered into the system by the clinical team. Outreach efforts can be 
conducted through electronic reminders, mail, or telephone to assist with scheduling and addressing 
screening concerns.(119) The collection of data on screening practices and breast cancer trends within 
the medical home can guide the delivery of preventive services, especially regarding current 
mammography utilization and geographic disparities. For example, women who live in rural areas of the 
US have a significantly lower rate of breast cancer screening compared to women living in urban 
areas.(120) Due to the limited time in an office visit, the use of multicultural and multilingual decision aids 
(video, online, and print education tools) can help address the barriers of health literacy and lack of 
knowledge about the benefits and risks of screening. Patient navigators, defined as those assigned to 
helping patients overcome barriers to care, can assist with patient education, language and cultural 
issues, scheduling appointments, transportation, or other logistical problems. The use of the EHR can 
also contribute to more effective cancer screening outreach efforts, such as identifying screening-eligible 
women and triggering follow-up of abnormal screening results.(119, 121) In a study investigating EHR 
use and quality measures, investigators found that breast cancer screening improved by nearly 4.5 
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percentage points in sites using EHRs.(122) 
 
Summary/Conclusion 
Risk stratification in breast cancer prevention and screening is a key component to reduce breast 
cancer mortality. Preventive measures such as physical activity, tobacco cessation, limiting alcohol use, 
and maintaining a healthy weight should continue to be emphasized as part of a healthy lifestyle and to 
minimize breast cancer risk. Chemoprevention with selective estrogen receptor modulators is also an 
important consideration for women who are at high risk for developing breast cancer. Identifying women 
who have a greater than average lifetime risk of breast cancer and referring them for genetic testing or 
counseling is a significant responsibility of the primary care provider. Given the variable guideline 
recommendations, a shared decision making model will increasingly become an essential tool for primary 
care providers in counseling patients on cancer screening options. Primary care providers will need to 
incorporate patients’ personal and family risk factors, individual preferences, and recommended 
guidelines to provide their patients with appropriate screening and risk reduction recommendations. While 
implementation of the Affordable Care Act provides an opportunity to increase screening rates, public 
health efforts should continue to develop a comprehensive and collaborative model to reduce health 
disparities in breast cancer screening, prevention, and treatment.  
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Table 1. Risk Factors for Breast Cancer 
 
Relative Risk 
 
Factor 
>4.0 • Age (65+ vs <65 years, although risk increases across 
all ages until age 80) 
• Biopsy-confirmed atypical hyperplasia 
• Certain inherited genetic mutations for breast cancer 
(BRCA1 and/or BRCA2) 
• Lobular carcinoma in situ 
• Mammographically dense breasts 
• Personal history of early onset (<40 years) breast cancer  
• Two or more first-degree relatives with breast cancer 
diagnosed at an early age 
2.1 - 4.0 • Personal history of breast cancer (40+ years) 
• High endogenous estrogen or testosterone levels 
(postmenopausal) 
• High dose radiation to chest 
• One first-degree relative with breast cancer 
1.1 - 2.0 • Alcohol consumption 
• Ashkenazi Jewish (Eastern European) heritage 
• Diethylstilbesterol (DES) exposure 
• Early menarche (age <12 years) 
• Height (tall) 
• High socioeconomic status 
• Late age at first pregnancy (age >30 years) 
• Late menopause (age >55 years) 
 22
• Never breastfed a child 
• No full-term pregnancies 
• Obesity (postmenopausal)/adult weight gain 
• Personal history of endometrium, ovary, or colon cancer 
• Recent and long-term use of menopausal hormone 
therapy containing estrogen and progestin 
• Recent oral contraceptive use 
Adapted from American Cancer Society. Breast Cancer Facts and Figures 2013-14. Atlanta (GA): 
American Cancer Society, Inc. 2013. p. 12   
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List 1. National Comprehensive Cancer Network® Criteria for Referral for Genetic 
Testing for Hereditary Breast and/or Ovarian Cancer Syndrome 
• Individual from family with known BRCA1/BRCA2 mutation 
• Personal history of breast cancer plus one or more of the following: 
o Diagnosed at age ≤45 years 
o Presence of two primary breast cancers when first breast cancer diagnosis 
occurred age ≤50 years 
o Diagnosed age ≤50 years with ≥1 close relativea with breast cancer at any 
age or with limited family history 
o Diagnosed age ≤60 years with a triple negative breast cancer 
o Diagnosed any age with ≥1 close relativea with breast cancer age ≤50 years 
o Diagnosed any age with ≥2 close relativesa with breast cancer at any age 
o Diagnosed any age with ≥1 close relativea with epithelial ovarian cancerb 
o Diagnosed any age with ≥2 close relativesa with pancreatic cancer or 
prostate cancerc at any age 
o Close male relativea with breast cancer 
o For individual of Ashkenazi-Jewish heritage, no additional family history may 
be required 
• Personal history of epithelial ovarian cancerb 
• Personal history of male breast cancer 
• Personal history of pancreatic cancer or prostate cancerc at any age with ≥2 close 
relativesa with breast and/or ovarianb and/or pancreatic or prostate cancerc at any 
age 
• Family history onlyd 
o First or second degree relative meeting any of above criteria 
o Third degree relative with breast cancer and/or ovarian cancera with ≥2 
close relativesa with breast cancer (at least one age ≤50 years) and/or 
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ovarian cancerb 
a
 First, second, or third-degree relative  
b
 Includes fallopian tube and primary peritoneal cancers  
c
 Gleason score ≥7 
d
 Significant limitations of interpreting test results for an unaffected individual should be discussed. 
Testing of unaffected individuals should only be considered when an appropriate affected family member 
is unavailable for testing. Clinical judgment should be used to determine if the patient has reasonable 
likelihood of a mutation, considering the unaffected patient's current age and the age of female unaffected 
relatives who link the patient with the affected relatives. 
Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 
for Genetic/Familial Risk Assessment: Breast and Ovarian V.4.2013. © 2013 National Comprehensive 
Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be 
reproduced in any form for any purpose without the express written permission of the NCCN. To view the 
most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NATIONAL 
COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN 
Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 
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 Table 2. National Comprehensive Cancer Network® Criteria for Referral for Genetic Risk 
Assessment 
An affected individual with one or more of 
the following: 
An unaffected individual with a family 
history of one or more of the following: 
• A known mutation in a breast cancer 
susceptibility gene within the family 
• A known mutation in a breast cancer 
susceptibility gene within the family 
• Early-age-onset breast cancer • ≥2 breast primaries in single 
individual 
• Triple negative (ER-/PR-/HER2-) 
breast cancer 
• ≥2 individuals with breast primaries 
on same side of family 
• Two breast cancer primaries in a 
single individual 
• ≥1 ovarian cancerb primary from the 
same side of family 
• Breast cancer at any age, and 
o ≥1 close relativea with breast 
cancer age ≤50years, or 
o ≥1 close relativea with 
epithelial ovarian cancerb at 
any age 
o ≥2 close relativesa with breast 
cancer and/or pancreatic 
cancer at any age 
o From a population at 
increased risk 
• First or second degree relative with 
breast cancer age ≤ 45 years 
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a
  First, second, or third-degree relative  
b
 Includes fallopian tube and primary peritoneal cancers  
c
 Gleason score ≥7 
Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 
for Genetic/Familial Risk Assessment: Breast and Ovarian V.4.2013. © 2013 National Comprehensive 
Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be 
reproduced in any form for any purpose without the express written permission of the NCCN. To view the 
most recent and complete version of the NCCN Guidelines, go online to NCCN.org. NATIONAL 
COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN 
Content are trademarks owned by the National Comprehensive Cancer Network, Inc.  
  
• ≥1 family member on same side of 
family with a combination of breast 
cancer and ≥1 of the following: 
pancreatic cancer, prostate cancer,c 
sarcoma, adrenocortical carcinoma, 
brain tumors, endometrial cancer, 
leukemia/lymphoma, thyroid cancer, 
dermatologic manifestatioins and/or 
macrocephaly, hamartomatous 
polyps of GI tract, diffuse gastric 
cancer 
• ≥1 family member on same side of 
family with a combination of breast 
cancer and ≥1 of the following: 
pancreatic cancer, prostate cancer,c 
sarcoma, adrenocortical carcinoma, 
brain tumors, endometrial cancer, 
leukemia/lymphoma, thyroid cancer, 
Cowden syndrome, hamartomatous 
polyps of GI tract, diffuse gastric 
cancer 
• Ovarian cancerb • Male breast cancer 
• Male breast cancer  
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Box 1. Resources for Genetic Testing and Genetic Counseling 
American Cancer Society—Genetic Testing: What You Need to Know  
• http://www.cancer.org/cancer/cancercauses/geneticsandcancer/genetictesting/genetic-testing-
what-you-need-to-know-toc 
National Society for Genetic Counselors—The “Consumer Information” link on the Web site has 
information on genetic counseling, questions to ask before genetic testing, a guide to collecting family 
history, info on genetic testing and genetic counselors, and a directory of genetic counselors 
• www.nsgc.org 
American Board for Genetic Counseling—Additional information on how to find a genetic counselor 
• http://www.abgc.net/ABGC/AmericanBoardofGeneticCounselors.asp  
National Cancer Institute—List of services related to cancer genetics (cancer risk assessment, genetic 
counseling, genetic susceptibility testing) 
•  www.cancer.gov/cancertopics/genetics/directory 
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From Refs. (27-62)  
  
List 2. Summary of Recommendations for Primary Prevention for Breast Cancer 
Factors that are associated with an increased risk of breast cancer: 
• Obesity (weight gain important, weight loss less clear)  
• Tobacco (current and previous use) 
• Alcohol use (3-14 drinks/week) 
Factors that are associated with a decreased risk of breast cancer: 
• Physical Activity (moderate to high levels)  
• Chemoprevention with SERMS (recommended for women age 35 or older at high risk for breast 
cancer and at low risk for medication adverse events such as thromboembolic disease) 
Factors that are associated with an unknown relation to risk of breast cancer: 
•  Dietary Content (fruits, vegetables, total fat, vitamins A, C, E, beta-carotene, antioxidants, 
carbohydrates, dairy soy) 
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a
 Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN 
Table 3. Summary of Screening Recommendations for Women at Average Risk from Breast 
Cancer 
Screen-
ing 
modality 
United 
States 
Preventa-
tive 
Services 
Task 
Force 
 
Canadian 
Task 
Force on 
the 
Periodic 
Health 
Examina-
tion 
 
American 
Cancer 
Society 
 
National 
Compre-
hensive 
Cancer 
Networka 
 
American 
Academy 
of Family 
Physi-
cians 
 
American 
College of 
Obstetri-
cians and 
Gynecol-
ogists 
 
American 
College of 
Radiology 
 
Breast self 
examina-
tion 
Do not 
recom-
mend 
Do not 
recom-
mend 
Breast 
self-
awareness 
encour-
aged 
Breast 
self-
awareness 
encour-
aged 
Do not 
recom-
mend 
Breast 
self-
awareness 
encour-
aged 
 
- 
Clinical 
breast 
examina-
tion 
Insufficient 
evidence 
Every 1-2 
years 
starting at 
age 40 
Every 3 
years from 
ages 20 to 
39, then 
annually  
Every 1-3 
years from 
ages 20 to 
39, then 
annually 
Insufficient 
evidence 
Every 1-3 
years from 
ages 20 to 
39, then 
annually 
 
 
- 
Mammog-
raphy 
Every 2 
years for 
women 
ages 50 to 
74  
Annually 
for women 
ages 50 to 
74  
Annually 
beginning 
at age 40 
Annually 
beginning 
at age 40 
Every 2 
years for 
women 
ages 50 to 
74  
Annually 
beginning 
at age 40 
Annually 
beginning 
at age 40 
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Guidelines®) for Breast Cancer Screening and Diagnosis V.2.2013. © National Comprehensive Cancer 
Network, Inc 2013. All rights reserved. Accessed [November 19, 2013]. To view the most recent and 
complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER 
NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the 
National Comprehensive Cancer Network, Inc. 
 Data from Tria Tirona M. Breast cancer screening update. Am Fam Physician 2013; 87(4):277. 
 
 
  
 31
 
Table 5. Screening and Risk Reduction Recommendations for Women at High Risk from 
Breast Cancer 
Risk Factor  Clinical Breast 
Examination 
Breast Self- 
Awareness 
Mammography MRI Risk 
Reduction 
Options 
BRCA 
mutation 
carrier 
Every 6 mos Yes Annually starting 
at age 25 
Annually 
starting 
at age 
25 
Mastectomy 
bilateral 
salpingo-
oophorectomy 
Tamoxifen/ 
raloxifene 
20% or 
greater 
lifetime risk  
Every 6– 2 mos Yes Annually starting 
5- 10 y before 
youngest breast 
cancer diagnosis 
in family 
Offer Tamoxifen/ 
raloxifene 
5 yr risk 
1.7% or 
greater 
based on 
Modified Gail 
Model 
Every 6–12 mos Yes Annually 
beginning at age 
40 
Offer Tamoxifen/ 
raloxifene 
History of 
thoracic 
ionizing 
radiation 
Every 6– 2 mos Yes Annually 
beginning at age 
25 or 8-10 yr 
after radiation 
exposure 
Offer  
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Abbreviations: LCIS, lobular carcinoma in situ; MRI, magnetic resonance imaging. 
 Adapted from Griffin JL, Pearlman MD. Breast cancer screening in women at average risk and high 
risk. Obstet Gynecol 2010; 116(6):1417; with persmission. 
 
 
  
Biopsy with 
LCIS or 
atypical 
hyperplasia 
Every 6–12 mos Yes Annually 
beginning at time 
of diagnosis 
Offer Tamoxifen/ 
raloxifene 
Mastectomy 
for LCISa 
(controversial) 
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